Alaunos Therapeutics (TCRT) Operating Leases (2020 - 2021)

Alaunos Therapeutics (TCRT) reported Operating Leases of $4.7 million for Q3 2021, down 3.74% quarter-over-quarter from $4.9 million in Q2 2021.

Alaunos Therapeutics (TCRT) Operating Leases (2020 - 2021) Analysis & Trends

Alaunos Therapeutics has reported Operating Leases for 2 years, with the latest figure at $4.7 million in Q3 2021.

For the quarter ending Q3 2021, Operating Leases changed N/A year-over-year to $4.7 million; the trailing twelve-month figure through Sep 2021 stood at $4.7 million (changed N/A YoY), and the FY2020 full-year result was $4.0 million, changed N/A from the prior year.
Operating Leases for Q3 2021 stood at $4.7 million, down from $4.9 million in the prior quarter.
The five-year high for Operating Leases was $4.9 million in Q2 2021, with the low at $4.0 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Alaunos Therapeutics	4.31 Mn	3.95 Mn	-

Download Data